These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9516823)

  • 21. The DDX1 gene maps within 400 kbp 5' to MYCN and is frequently coamplified in human neuroblastoma.
    Amler LC; Schürmann J; Schwab M
    Genes Chromosomes Cancer; 1996 Feb; 15(2):134-7. PubMed ID: 8834178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of MRP and cMOAT in childhood neuroblastomas and malignant liver tumors and its relevance to clinical behavior.
    Matsunaga T; Shirasawa H; Hishiki T; Enomoto H; Kouchi K; Ohtsuka Y; Iwai J; Yoshida H; Tanabe M; Kobayashi S; Asano T; Etoh T; Nishi Y; Ohnuma N
    Jpn J Cancer Res; 1998 Dec; 89(12):1276-83. PubMed ID: 10081488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma.
    Shohet JM; Hicks MJ; Plon SE; Burlingame SM; Stuart S; Chen SY; Brenner MK; Nuchtern JG
    Cancer Res; 2002 Feb; 62(4):1123-8. PubMed ID: 11861392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro effects of MYCN sense and antisense expression in MYCN-amplified human neuroblastoma cells.
    Kavallaris M; Gardaneh M; Cheung B; Camacho ML; Hocker JE; Norris MD; Haber M; Marshall GM
    Anticancer Res; 1998; 18(3A):1793-7. PubMed ID: 9673406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of P27(KIP1) is prognostic and independent of MYCN amplification in human neuroblastoma.
    Bergmann E; Wanzel M; Weber A; Shin I; Christiansen H; Eilers M
    Int J Cancer; 2001 May; 95(3):176-83. PubMed ID: 11307151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma.
    Duffy DJ; Krstic A; Halasz M; Schwarzl T; Fey D; Iljin K; Mehta JP; Killick K; Whilde J; Turriziani B; Haapa-Paananen S; Fey V; Fischer M; Westermann F; Henrich KO; Bannert S; Higgins DG; Kolch W
    Oncotarget; 2015 Dec; 6(41):43182-201. PubMed ID: 26673823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression analysis of multidrug resistance associated genes in neuroblastomas.
    Bader P; Schilling F; Schlaud M; Girgert R; Handgretinger R; Klingebiel T; Treuner J; Liu C; Niethammer D; Beck JF
    Oncol Rep; 1999; 6(5):1143-6. PubMed ID: 10425316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different effects of TrkA expression in neuroblastoma cell lines with or without MYCN amplification.
    Eggert A; Ho R; Ikegaki N; Liu XG; Brodeur GM
    Med Pediatr Oncol; 2000 Dec; 35(6):623-7. PubMed ID: 11107132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
    Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
    Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The prognostic effect of amplification of the MYCN oncogene in neuroblastoma. The preliminary results of the Italian Cooperative Group for Neuroblastoma (GCINB)].
    Pession A; De Bernardi B; Perri P; Mazzocco K; Rondelli R; Nigro M; Iolascon A; Forni M; Basso G; Conte M
    Pediatr Med Chir; 1994; 16(3):211-8. PubMed ID: 7971442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.
    Moreau LA; McGrady P; London WB; Shimada H; Cohn SL; Maris JM; Diller L; Look AT; George RE
    Clin Cancer Res; 2006 Oct; 12(19):5693-7. PubMed ID: 17020972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.
    Weber A; Imisch P; Bergmann E; Christiansen H
    J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma.
    Kramer K; Cheung NK; Gerald WL; LaQuaglia M; Kushner BH; LeClerc JM; LeSauter L; Saragovi HU
    Eur J Cancer; 1997 Oct; 33(12):2098-100. PubMed ID: 9516861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).
    Rubie H; Delattre O; Hartmann O; Combaret V; Michon J; Bénard J; Peyroulet MC; Plantaz D; Coze C; Chastagner P; Baranzelli MC; Frappaz D; Lemerle J; Sommelet D
    Eur J Cancer; 1997 Oct; 33(12):1917-22. PubMed ID: 9516824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group.
    George RE; Variend S; Cullinane C; Cotterill SJ; McGuckin AG; Ellershaw C; Lunec J; Pearson AD;
    Med Pediatr Oncol; 2001 Jan; 36(1):169-76. PubMed ID: 11464876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification.
    Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A
    J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of candidate gene co-amplification with MYCN in neuroblastoma.
    George RE; Kenyon R; McGuckin AG; Kohl N; Kogner P; Christiansen H; Pearson AD; Lunec J
    Eur J Cancer; 1997 Oct; 33(12):2037-42. PubMed ID: 9516849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma.
    Fulda S; Poremba C; Berwanger B; Häcker S; Eilers M; Christiansen H; Hero B; Debatin KM
    Cancer Res; 2006 Oct; 66(20):10016-23. PubMed ID: 17047064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.